Lv3
220 积分 2023-01-05 加入
Bispecific antibody based therapeutics: Strengths and challenges
4天前
已完结
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial
11天前
已完结
Can oral GLP-1 receptor agonists ACHIEVE the same as SGLT2 inhibitors?
11天前
已完结
Taming the inflamed heart
11天前
已完结
Can oral GLP-1 receptor agonists ACHIEVE the same as SGLT2 inhibitors?
18天前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
18天前
已完结
Correspondence - Tranexamic acid for traumatic brain injury
18天前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
18天前
已完结
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
19天前
已完结
Resetting autoimmune disease with CAR cell therapies
19天前
已完结
皖公网安备34019202002308
